Angioedema Workup and Treatment
For any patient presenting with angioedema, immediately assess airway patency and secure the airway if there is any laryngeal involvement, as this is a life-threatening emergency that can lead to asphyxiation. 1
Diagnostic Workup Algorithm
The diagnostic approach follows a systematic 8-step algorithm to differentiate between types of angioedema 1:
Step 1: Confirm True Angioedema
- Document recurrent angioedema WITHOUT hives (presence of hives suggests mast cell-mediated disease)
- Obtain photographic evidence, laryngoscopic findings, or imaging during attacks to exclude factitious angioedema
- For abdominal attacks: obtain CT imaging during episodes to document bowel wall edema and intraperitoneal fluid
- Obtain detailed family history (recurrent angioedema in relatives) and complete medication history
Step 2: Exclude C1-Inhibitor Deficiency
Measure the following labs even if patient is on suspected culprit medications 1:
- C4 level
- C1-INH antigen
- C1-INH function (if available)
If acquired C1-INH deficiency suspected (symptom onset >40 years):
- C1q level
- Anti-C1-INH antibodies
- Consider SERPING1 sequencing to distinguish acquired from hereditary forms
Step 3: Exclude Medication-Associated Angioedema
Stop ALL potential culprit drugs and observe for 1-3 months (response may be delayed) 1:
- ACE inhibitors
- Angiotensin receptor blockers
- Dipeptidyl peptidase-4 inhibitors
- Neprilysin inhibitors
- Tissue plasminogen activators
- NSAIDs
Step 4: Assess Family History
If strong family history of recurrent angioedema exists, proceed directly to targeted gene sequencing (Step 6) 1
Step 5: Exclude Mast Cell-Mediated Angioedema
Trial of mast cell-directed therapy in this specific order 1:
- Second-generation H1-antihistamine at 4× standard dose for sufficient duration to assess effect
- If fails: Add daily montelukast (unless contraindicated)
- If still unresponsive: Omalizumab for 4-6 months
Response to any of these confirms mast cell-mediated angioedema. If no response, consult an angioedema expert before proceeding.
Step 6: Targeted Gene Sequencing
If accessible and cost-effective, perform next-generation sequencing or Sanger sequencing for known HAE pathogenic variants (F12, ANGPT1, PLG, KNG1, MYOF, HS3ST6) 1:
- Known pathogenic variant = HAE-nC1INH diagnosis confirmed
- Novel variant = variant of unknown significance (requires research confirmation)
- Depending on cost/availability, may perform before omalizumab trial
Step 7: Therapeutic Trial with Bradykinin B2 Receptor Antagonist
For patients without identified pathogenic variant 1:
- Prompt and durable response to icatibant or other HAE on-demand treatment supports bradykinin-mediated angioedema
- Lack of response does NOT exclude HAE
- Consider trial of second on-demand medication or long-term prophylaxis (tranexamic acid)
Classification:
- Positive family history = HAE-UNK (hereditary angioedema of unknown cause)
- Negative family history = INMA (idiopathic non-mast cell-mediated angioedema)
Step 8: Screen Family Members
When HAE-nC1INH diagnosed, screen all relatives by:
- Clinical history for angioedema symptoms
- Female relatives: history of swelling during pregnancy or estrogen use
- Targeted genetic screening if pathogenic variant identified 1
Acute Treatment by Angioedema Type
Bradykinin-Mediated Angioedema (HAE)
First-line on-demand treatment 2, 3, 4:
- Bradykinin B2 receptor antagonist (icatibant) - subcutaneous, can be self-administered
- Plasma kallikrein inhibitor (ecallantide) - subcutaneous, healthcare provider administration
- C1-INH concentrate (plasma-derived or recombinant) - intravenous
Critical point: Antihistamines, corticosteroids, and epinephrine are INEFFECTIVE for bradykinin-mediated angioedema 5, 3, 4
Airway management: If laryngeal involvement, intubation may be extremely difficult; consider early tracheostomy consultation 6, 5
Histamine-Mediated (Allergic) Angioedema
- Epinephrine (if anaphylaxis or severe reaction)
- H1-antihistamines (first or second generation)
- H2-antihistamines (adjunctive)
- Corticosteroids
ACE Inhibitor-Induced Angioedema
- Discontinue ACE inhibitor immediately
- Avoid all ACE inhibitors and ARBs permanently
- Acute treatment: Fresh frozen plasma or icatibant (off-label but evidence-supported) 5, 4
- Antihistamines and corticosteroids typically ineffective 5, 3
Common Pitfalls to Avoid
Do NOT delay airway assessment - laryngeal angioedema can progress rapidly to complete obstruction 6, 5
Do NOT treat bradykinin-mediated angioedema with antihistamines/steroids/epinephrine - this wastes critical time and provides no benefit 5, 3, 4
Do NOT assume absence of family history excludes HAE - up to 25% of HAE cases are de novo mutations 1
Do NOT stop workup after excluding C1-INH deficiency - HAE with normal C1-INH exists and requires different management 1
Do NOT restart ACE inhibitors after ACE inhibitor-induced angioedema - recurrence risk is high and can be fatal 5
Do NOT wait months to assess medication-associated angioedema - while 1-3 months observation is typical, some patients may take longer depending on attack frequency 1
Do NOT misdiagnose factitious angioedema as HAE - this is common; always obtain objective documentation (photos, imaging, laryngoscopy) 1
Treatment Goals
The modern paradigm emphasizes complete disease control and normalization of quality of life, not merely reduction in attack frequency 7, 8. This includes:
- Minimizing attack frequency, severity, and duration
- Enabling normal daily activities
- Facilitating home-based self-treatment when appropriate
- Patient-centered, individualized approach based on disease burden
For HAE patients: Consider long-term prophylaxis if attacks significantly impact quality of life, occur frequently, or involve high-risk locations (laryngeal) 8